Clinical Trials Logo

Metastatic NSCLC clinical trials

View clinical trials related to Metastatic NSCLC.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05617313 Suspended - Clinical trials for Non Small Cell Lung Cancer

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Start date: February 17, 2023
Phase: Phase 2
Study type: Interventional

This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC. The study will consist of a safety lead-in of 10-20 patients. A total of 50 patients will be treated with the combination at the safest dose of GT103 as determined in the safety lead-in. If 10 additional patients are enrolled to the dose level -1 then the maximum of 60 subjects may be accrued to this trial.